ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: INFO16

Cure Glomerulonephropathy Network (CureGN)

Session Information

  • Informational Posters
    October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM


  • No subcategory defined


  • Fernandez, Hilda E., NYP-CUMC, New York, New York, United States
  • Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
  • Richardson, Kelsey L., Oregon Health & Science University, Portland, Oregon, United States
  • O'Shaughnessy, Michelle M., Stanford University, Palo Alto, California, United States
  • Reidy, Kimberly J., Children's Hospital at Montefiore/ Albert Einstein College of Medicine, Bronxville, New York, United States
  • Glenn, Dorey A., University of North Carolina, Chapel Hill, North Carolina, United States
  • Levy, Rebecca, Montefiore Medical Center, New York, New York, United States
  • Laurin, Louis-Philippe, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Group or Team Name

  • On Behalf of the CureGN Consortium

Cure GlomeruloNephropathy (CureGN) is a multi-center, prospective observational study of glomerular disease funded by the NIH-NIDDK. CureGN will enroll 2,400 children and adults from 70 sites, with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy/vasculitis (IgAN/IgAV) from the USA, Canada, Italy, and Poland. Patients whose first diagnostic kidney biopsy was within 5 years are eligible. Patients with end-stage kidney disease (ESKD) at enrollment or a secondary cause of glomerular disease are excluded. Visits are conducted 3 times a year with at least one visit in person and a max of two by telephone. Clinical data, patient-reported data, and biospecimens are collected, including outcomes of ESKD, death, and non-renal complications, including infection, malignancy, cardiovascular and thromboembolic events.

Enrollment began 12/2014. Participant demographic and outcome data as of 3/2018 are shown in Table 1. The Digital Pathology Repository (DPR) at the CureGN image coordinating center (CureGN-ICC) collects cases as a shared tool among all investigators. The DPR will be used to provide standardized scoring of biopsies, and will be critical for ancillary studies, with 379 cases to date.

CureGN supports clinical and translational research by combining detailed clinical data with a biorepository of DNA, RNA, blood, and urine specimens as well as a digital archive of biopsy images. The study objectives support a variety of approaches to identify mechanistically distinct subgroups, define accurate biomarkers of disease activity, delineate disease-specific treatment targets and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular disease.


  • Funding for the CureGN consortium is provided by UM1DK100845, UM1DK100846, UM1DK100876, UM1DK100866, and UM1DK100867 from the NIDDK. Patient Recruitment is supported by NephCure Kidney International